Pinup®Voriconazole Tablets
Pinup®, the first antifungal drug developed by Uni-Bio Science Group, received bioequivalence approval from the China NMPA in December 2020 and was among the first to be selected in the Fourth Batch of the National Centralized Procurement of Drugs.
Pinup® represent a broad-spectrum triazole antifungal agent indicated for the treatment of the following fungal infections in adult and pediatric patients aged 2 years and older:
Invasive aspergillosis.
Candidemia in non-neutropenic patients.
Serious invasive infections caused by Candida species resistant to fluconazole (including C. krusei).
Severe infections due to Scedosporium species and Fusarium species.
*This product is intended primarily for the treatment of progressive, potentially life-threatening fungal infections.
*It is also indicated for the prevention of invasive fungal infections in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
50mg
Mechanism of Action
The primary mechanism of voriconazole involves inhibition of cytochrome P450-mediated 14α-sterol demethylation in fungi, thereby blocking ergosterol biosynthesis. In vitro studies demonstrate broad-spectrum antifungal activity, exhibiting fungistatic action against Candida species (including fluconazole-resistant C. krusei, C. glabrata, and resistant strains of C. albicans) and fungicidal activity against all tested Aspergillus species. Additionally, voriconazole shows fungicidal effects in vitro against other pathogenic fungi with reduced susceptibility to existing agents, such as Scedosporium and Fusarium species.
Product Advantages
-
First-line treatment for invasive aspergillosis -
Demonstrated broad-spectrum in vitro antifungal activity -
Therapeutically equivalent to the reference product with assured quality
More Products
-
Pinup®Voriconazole TabletsPinup® represent a broad-spectrum triazole antifungal agent indicated for the treatment of the following fungal infections in adult and pediatric patients aged 2 years and older
-
Boshutai®Acarbose TabletsAs an adjunct to dietary control for: (1) Type 2 diabetes (2) Reducing postprandial blood glucose in individuals with impaired glucose tolerance
-
金因康®Diquafosol Sodium Eye Drops金因康® is indicated for patients diagnosed with dry eye accompanied by keratoconjunctival epithelial damage associated with tear deficiency.
